Fentanyl action: U.S sanctions Chinese, Mexican entities
The United States has imposed sanctions on 17 people and entities based in China and Mexico for enabling the production of counterfeit fentanyl-laced pills.
The Treasury Department said it slapped sanctions on seven entities and six people based in China, as well as one business and three people based in Mexico.
It accused those targeted of being involved in the sale of pill press machines and other equipment used to impress counterfeit trade markings like Xanax and M30 onto illicitly produced pills, often laced with fentanyl and destined for the United States.
“Treasury’s sanctions target every stage of the deadly supply chain fueling the surge in fentanyl poisonings and deaths across the country,” Treasury’s Under Secretary for Terrorism and Financial Intelligence Brian Nelson said in a statement.
“Counterfeit pills laced with fentanyl constitute a leading cause of these deaths, devastating thousands of American families each year. We remain committed to using all authorities against enablers of illicit drug production to disrupt this deadly global production and counter the threat posed by these drugs.”
The rate of drug overdose deaths involving the synthetic opioid fentanyl more than tripled in the United States from 2016 through 2021, according to a report by the U.S. Centers for Disease Control and Prevention (CDC) released this month.
Also Read: Mexico, U.S discuss migration, security
Fentanyl is up to 50 times stronger than heroin and 100 times stronger than morphine, and has increasingly been mixed with other illicit drugs often with lethal results.
The Biden administration has been pushing for action as U.S. drug-related overdose deaths surpassed 100,000 in 2021, according to government estimates.
Washington has been seeking greater help from Beijing in stemming the illicit flow of fentanyl “precursor” chemicals from China, but U.S. officials say that Chinese counterparts have been reluctant to cooperate as relations between the two countries have soured.
The spokesperson for China’s Washington embassy, Liu Pengyu, condemned the Treasury move, saying Washington had “brazenly sanctioned Chinese individuals and entities” and this would “add more obstacles to China-US counter-narcotics cooperation.”
Liu called it “a serious violation of the lawful rights and interests of the companies and individuals concerned” and said Washington was attempting to deflect blame instead of working to reduce the demand and strengthen management of prescription drugs.
